EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

A randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy of the synbiotic medical food, SBD111, for the clinical dietary management of bone loss in menopausal women

Eric M Schott, Mark R Charbonneau, Douglas P Kiel, Susan Bukata, Michael J Zuscik, Clifford Rosen, Alicia Ballok, Gerardo V Toledo, Elizabeth Steels, Harry Huntress, Amanda Rao, Phillippa Ebelt und 6 weitere

Osteoporosis International · 2025

DOI: 10.1007/s00198-025-07650-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Osteoporosis International, 2025. Verfasst von Eric M Schott und 17 weiteren Autor:innen. Beteiligte Einrichtung: Solarea Bio, Inc., Waltham, MA, 02453, USA. eschott@solareabio.com. Hauptthemen laut MEDLINE: Synbiotics, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This 12-month study in 286 early postmenopausal women evaluated the efficacy and safety of SBD111, a synbiotic medical food, in reducing bone loss. SBD111 did not significantly reduce bone loss for the full cohort, but did produce evidence of reduced bone loss in women with osteopenia and BMI ≥ 30. PURPOSE: To determine the efficacy of SBD111, a synbiotic medical food comprising probiotics and prebiotics, in reducing bone loss in women post-menopause, including prespecified subpopulations of women with osteopenia or elevated BMI. METHODS: In this prospective, multicenter, double-blind, randomized, placebo-controlled clinical food trial (NCT05009875), 286 healthy, non-osteoporotic women between 1 and 6 years post-menopause were enrolled and consumed SBD111 (4.75 × 1010 colony forming units) or placebo (maltodextrin) capsules twice daily for 12 months. The primary endpoint was change in areal BMD at the lumbar spine (LS). Secondary endpoints included change in areal BMD at the femoral neck (FN) and total hip (TH), trabecular volumetric BMD at the LS, markers of bone turnover and inflammation, and safety. Changes in gut microbiome composition were exploratory. The hypotheses being tested were formulated before data collection. RESULTS: Two hundred eighty-six women [age 55 ± 3 years (mean ± standard deviation)] were enrolled, with 221 (77%) completing the study. For the primary outcome, SBD111 administration was not associated with significantly less bone loss in the LS after 12 months [0.15% (- 0.52%, 0.82%), mean effect size (95% CI) by linear mixed-effects regression]. However, SBD111 was associated with reduced BMD loss in the TH for women with BMI ≥ 30 [0.97% (0.015%, 1.925%)] and modestly reduced BMD loss in the FN for women with osteopenia [0.89% (- 0.277%, 2.051%)]. CONCLUSIONS: These findings indicate SBD111 did not significantly reduce BMD loss for the full cohort. However, the trial produced evidence that SBD111 reduced bone loss in women with osteopenia and BMI ≥ 30.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SynbioticsOsteoporosis, PostmenopausalHumansFemaleDouble-Blind MethodMiddle AgedBone DensityBone Diseases, MetabolicLumbar VertebraeProspective StudiesBody Mass IndexAbsorptiometry, PhotonFemur NeckProbioticsAged

Stichwörter der Autor:innen

Bone mineral density (BMD)OsteoporosisShort-chain fatty acids (SCFA)Tumor necrosis factor alpha (TNF-α)

Autor:innen und Institutionen

  • Solarea Bio, Inc., Waltham, MA, 02453, USA. eschott@solareabio.com.
  • Solarea Bio, Inc., Waltham, MA, 02453, USA.
  • Hinda and Arthur Marcus Institute for Aging Research, Hebrew Senior Life, Boston, MA, 02131, USA.
  • Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States.
  • School of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.
  • Department of Orthopedics, Colorado Program for Musculoskeletal Research, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.

Zitieren

APA

Schott, E. M., Charbonneau, M. R., Kiel, D. P., Bukata, S., Zuscik, M. J., Rosen, C., Ballok, A., Toledo, G. V., Steels, E., Huntress, H., Rao, A., Ebelt, P., Travison, T. G., Soto-Giron, M. J., Wolff, I., Easson, D. D., Engelke, K., & Vitetta, L. (2025). A randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy of the synbiotic medical food, SBD111, for the clinical dietary management of bone loss in menopausal women. Osteoporosis International. https://doi.org/10.1007/s00198-025-07650-7

Vancouver

Schott EM, Charbonneau MR, Kiel DP, Bukata S, Zuscik MJ, Rosen C, et al. A randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy of the synbiotic medical food, SBD111, for the clinical dietary management of bone loss in menopausal women. Osteoporosis International. 2025. doi:10.1007/s00198-025-07650-7

BibTeX
@article{Schott2025,
  author = {Schott, Eric M and Charbonneau, Mark R and Kiel, Douglas P and Bukata, Susan and Zuscik, Michael J and Rosen, Clifford and Ballok, Alicia and Toledo, Gerardo V and Steels, Elizabeth and Huntress, Harry and Rao, Amanda and Ebelt, Phillippa and Travison, Thomas G and Soto-Giron, Maria J and Wolff, Ian and Easson, D Davidson and Engelke, Klaus and Vitetta, Luis},
  title = {A randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy of the synbiotic medical food, SBD111, for the clinical dietary management of bone loss in menopausal women},
  journal = {Osteoporosis International},
  year = {2025},
  doi = {10.1007/s00198-025-07650-7}
}
Kostenlos starten →